Cephalon, Mylan, Ranbaxy Ink Combined $65.8M Provigil Deal
Proposed consumer classes have reached a $65.8 million deal in a suit claiming Mylan and Ranbaxy participated in pay-for-delay deals with Cephalon to prevent the sale of generic versions of the...To view the full article, register now.
Already a subscriber? Click here to view full article